Kathryn Farguson, DO
Cardiovascular Disease · Bartlesville, OKNPI 1912299041
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,574 and has fallen 58.2% since, to $657 in 2025.
Across 404 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$871
- Abbott$743
- Boehringer Ingelheim$531
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$527
- Pfizer$417
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,00298%
- Education$1552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 80 | $1,274 |
| Johnson & Johnson | 52 | $871 |
| Abbott | 30 | $743 |
| Boehringer Ingelheim | 29 | $531 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $527 |
| Pfizer | 27 | $417 |
| Merck | 26 | $377 |
| Amarin Pharma, Inc. | 17 | $251 |
| Astellas Pharma US Inc | 6 | $222 |
| Medtronic(2 entities) | 10 | $205 |
| AstraZeneca | 14 | $191 |
| Boston Scientific | 5 | $146 |
| Abiomed | 3 | $142 |
| Sanofi-aventis U.S. LLC | 7 | $139 |
| Alnylam Pharmaceuticals Inc. | 7 | $127 |
| Novo Nordisk | 8 | $125 |
| Amgen | 7 | $122 |
| E.r. Squibb & Sons, L.L.C. | 8 | $107 |
| Bayer | 7 | $100 |
| Lexicon Pharmaceuticals, Inc. | 4 | $83 |
| Cvrx, Inc. | 1 | $80 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Kestra Medical Technology Services, Inc. | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Irhythm Technologies, Inc. | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Surmodics, Inc. | 2 | $21 |
| United Therapeutics Corporation | 1 | $20 |
| Insmed, Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Livanova USA, Inc. | 1 | $13 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,157 in reported general payments places this provider in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $116,008 |
| XareltoRivaroxaban | 52 | $48,700 |
| EntrestoSacubitril/Valsartan | 25 | $32,656 |
| FarxigaDapagliflozin Propanediol | 12 | $10,820 |
| Ranolazine ErRanolazine | 63 | $7,047 |
| Repatha SureclickEvolocumab | 12 | $6,627 |
| Carvedilol | 268 | $2,647 |
| Lisinopril | 176 | $1,891 |
| Atorvastatin Calcium | 120 | $1,559 |
| Metoprolol Succinate | 110 | $1,389 |
| Nifedipine ErNifedipine | 44 | $1,330 |
| Losartan Potassium | 102 | $1,218 |
| ClopidogrelClopidogrel Bisulfate | 51 | $817 |
| Amiodarone Hcl | 18 | $794 |
| Metoprolol Tartrate | 113 | $725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $417 | $116,008140 claims |
| Johnson & JohnsonXarelto | $871 | $48,70052 claims |
| NovartisEntresto | $1,274 | $32,65625 claims |
| AstraZenecaFarxiga | $191 | $10,82012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Bartlesville
- Anderson MehrleBartlesville$129K
- Frank GaffneyTulsa$211K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
- Reji PappyOklahoma City$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.